Patents by Inventor Clarence S. Rooney

Clarence S. Rooney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of HIV reverse transcriptase
    Patent number: 5527819
    Abstract: Novel indole compounds inhibit HIV reverse transcriptase, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 18, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Theresa M. Williams, Terrence M. Ciccarone, Walfred S. Saari, John S. Wai, William J. Greenlee, Suresh K. Balani, Mark E. Goldman, Anthony D. Theoharides, deceased, Jacob M. Hoffman, Jr., William C. Lumma, Jr., Joel R. Huff, Clarence S. Rooney, Philip E. Sanderson
  • Inhibitors of HIV reverse transcriptase
    Patent number: 5308854
    Abstract: Novel aminopyridones inhibit HIV reverse transcriptase, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: November 4, 1992
    Date of Patent: May 3, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Jacob M. Hoffman, Jr., Walfred S. Saari, Clarence S. Rooney, John S. Wai
  • Heterobicyclic sulfonamides
    Patent number: 5276025
    Abstract: Compounds of general formula: ##STR1## are topically effective carbonic anhydrase inhibitors useful in the treatment of ocular hypertension and related disorders such as glaucoma.
    Type: Grant
    Filed: September 9, 1992
    Date of Patent: January 4, 1994
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Jacob M. Hoffman, Jr., James H. Jones, Clarence S. Rooney, Anthony M. Smith
  • Antihypercholesterolemic compounds
    Patent number: 5049696
    Abstract: Novel 3-hydroxy-3-methylglutaryl-Coenzyme A(HMG-CoA) reductase inhibitors, which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II) ##STR1## and pharmaceutically acceptable salts of the compound (II) in which Z is hydrogen are disclosed.
    Type: Grant
    Filed: June 14, 1989
    Date of Patent: September 17, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Ta J. Lee, Clarence S. Rooney, William F. Hoffman
  • Novel HMG-CoA reductase inhibitors
    Patent number: 4946864
    Abstract: Novel HMG-CoA reductase inhibitors of formulae (I) and (II) are disclosed.
    Type: Grant
    Filed: February 1, 1988
    Date of Patent: August 7, 1990
    Assignee: Merck & Co., Inc.
    Inventors: John Prugh, Albert A. Deana, Clarence S. Rooney
  • Antihypercholesterolemic compounds
    Patent number: 4937264
    Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1## and pharmaceutically acceptable salts of the compounds (II) in which Z is hydrogen are disclosed.
    Type: Grant
    Filed: June 30, 1989
    Date of Patent: June 26, 1990
    Assignee: Merck & Co., Inc.
    Inventors: William F. Hoffman, Ta J. Lee, Clarence S. Rooney
  • Antihypercholesterolemic compounds
    Patent number: 4937263
    Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1## and pharmaceutically acceptable salts of the compounds (II) in which Z is hydrogen are disclosed.
    Type: Grant
    Filed: July 17, 1989
    Date of Patent: June 26, 1990
    Assignee: Merck & Co., Inc.
    Inventors: William F. Hoffman, Ta J. Lee, Robert L. Smith, Clarence S. Rooney
  • Antihypercholesterolemic compounds
    Patent number: 4916162
    Abstract: Novel 3-hydroxy-3-methylglutary-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1## and pharmaceutically acceptable salts of the compounds (II) in which Z is hydrogen are disclosed.
    Type: Grant
    Filed: July 18, 1988
    Date of Patent: April 10, 1990
    Assignee: Merck & Co., Inc.
    Inventors: William F. Hoffman, Clarence S. Rooney, Ta Jyh Lee
  • Antihypercholesterolemic compounds
    Patent number: 4876366
    Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1## and pharmaceutically acceptable salts of the compounds (II) in which Z is hydrogen are disclosed.
    Type: Grant
    Filed: June 10, 1988
    Date of Patent: October 24, 1989
    Assignee: Merck & Co., Inc.
    Inventors: William F. Hoffman, Ta J. Lee, Robert L. Smith, Clarence S. Rooney
  • Antihypercholesterolemic compounds
    Patent number: 4876279
    Abstract: Novel 3-hydroxy-3-methylglutaryl-Coenzyme A(HMG-CoA) reductase inhibitors, which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II) ##STR1## and pharmaceutically acceptable salts of the compound (II) in which Z is hydrogen are disclosed.
    Type: Grant
    Filed: May 26, 1988
    Date of Patent: October 24, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Ta J. Lee, William F. Hoffman, Clarence S. Rooney
  • Novel HMG-CoA reductase inhibitors
    Patent number: 4866068
    Abstract: Novel HMG-CoA reductase inhibitors of formulae (I) and (II) are disclosed: ##STR1##
    Type: Grant
    Filed: February 1, 1988
    Date of Patent: September 12, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Clarence S. Rooney
  • Antihypercholesterolemic compounds
    Patent number: 4864038
    Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1## and pharmaceutically acceptable salts of the compounds (II) in which Z is hydrogen are disclosed.
    Type: Grant
    Filed: June 10, 1988
    Date of Patent: September 5, 1989
    Assignee: Merck & Co., Inc.
    Inventors: William F. Hoffman, Ta J. Lee, Clarence S. Rooney
  • Antihypercholesterolemic compounds
    Patent number: 4847306
    Abstract: Novel 3-hydroxy-3-methylglutaryl-Coenzyme A(HMG-CoA) reductase inhibitors, which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II) ##STR1## and pharmaceutically acceptable salts of the compound (II) in which Z is hydrogen are disclosed.
    Type: Grant
    Filed: April 11, 1988
    Date of Patent: July 11, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Ta J. Lee, Clarence S. Rooney, William F. Hoffman
  • 6H-dibenz[b,e][1,4]oxathiepin compounds
    Patent number: 4778897
    Abstract: Novel 6H-dibenz[b,e][1,4]oxathiepin derivatives of the formulae I and Ia are employed in the treatment and control of allergic conditions such as allergic asthma.
    Type: Grant
    Filed: May 28, 1987
    Date of Patent: October 18, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Edward J. Cragoe, Jr., Clarence S. Rooney, Joshua Rokach
  • Antihypercholesterolemic compounds
    Patent number: 4771071
    Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1## and pharmaceutically acceptable salts of the compounds (II) in which Z is hydrogen are disclosed.
    Type: Grant
    Filed: May 5, 1986
    Date of Patent: September 13, 1988
    Assignee: Merck & Co., Inc.
    Inventors: William F. Hoffman, Clarence S. Rooney, Ta J. Lee
  • Antihypercholesterolemic compounds
    Patent number: 4766145
    Abstract: Novel 3-hydroxy-3-methylglutaryl-Coenzyme A(HMG-CoA) reductase inhibitors, which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II) ##STR1## and pharmaceutically acceptable salts of the compound (II) in which Z is hydrogen are disclosed.
    Type: Grant
    Filed: May 5, 1986
    Date of Patent: August 23, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Ta J. Lee, Clarence S. Rooney, William F. Hoffman
  • Anti-asthmatic tetrazolyl 6H-dibenz-[B,E]-[1,4]-oxathiepin derivatives, compositions, and method of use therefor
    Patent number: 4699917
    Abstract: Novel 6H-dibenz[b,e][1,4]oxathiepin derivatives of the formulae I and Ia are employed in the treatment and control of allergic conditions such as allergic asthma.
    Type: Grant
    Filed: January 9, 1986
    Date of Patent: October 13, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Edward J. Cragoe, Jr., Clarence S. Rooney, Joshua Rokach
  • Antihypercholesterolemic lactone compounds, compositions and use
    Patent number: 4661483
    Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1## and pharmaceutically acceptable salts of the compounds (II) in which Z is hydrogen are disclosed.
    Type: Grant
    Filed: May 5, 1986
    Date of Patent: April 28, 1987
    Assignee: Merck & Co., Inc.
    Inventors: William F. Hoffman, Clarence S. Rooney, Ta J. Lee
  • Anti-asthmatic 6H-dibenz-[b,e] [1,4]oxathiepin derivatives, compositions, and method of use therefor
    Patent number: 4582842
    Abstract: Novel 6H-dibenz[b,e] [1,4]oxathiepin derivatives of the formula I and Ia are employed in the treatment and control of allergic conditions such as allergic asthma.
    Type: Grant
    Filed: September 26, 1983
    Date of Patent: April 15, 1986
    Assignees: Merck & Co., Inc., Merck Frosst Canada
    Inventors: Edward J. Cragoe, Jr., Clarence S. Rooney
  • 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
    Patent number: 4537902
    Abstract: Novel 4-substituted-3-hydroxy-3-pyrroline-2,5-diones are disclosed which inhibit glycolic acid oxidase and thus are useful in the treatment and prevention of calcium oxalate renal lithiasis.
    Type: Grant
    Filed: June 11, 1979
    Date of Patent: August 27, 1985
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme (I.A.) Corp.
    Inventors: Edward J. Cragoe, Jr., Clarence S. Rooney, Haydn W. R. Williams